The specialty chemicals company Clariant has broken the ground for its new investment in Konstantynów Łódźki, Poland. The new building covers an area about 6'800 square meters and will include new production site, laboratory and warehouse as well as Clariant offices.
The investment, worth CHF 11.3 million, will enable Clariant to double the production capacity of color concentrates for its Business Unit Masterbatches and also to create new job opportunities.
Eli Lilly plans to invest $27 billion to bolster its domestic medicine production across several therapeutic areas by building four new manufacturing sites in the US.
US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.
Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.
Samsung Biologics, a global contract development and manufacturing organization (CDMO), recently announced a series of manufacturing deals with a Europe-based pharmaceutical company.
Europe's chemical industry is in crisis, warns the European Chemical Industry Council (CEFIC) President Ilham Kadri, urging EU leaders to act on a 10-point rescue plan to prevent further shutdowns and loss of investments.
